Logo image of QNRX

QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Fundamental Analysis

NASDAQ:QNRX - Nasdaq - US74907L3006 - ADR - Currency: USD

0.3193  -0.01 (-4.06%)

After market: 0.3213 +0 (+0.63%)

Fundamental Rating

2

Overall QNRX gets a fundamental rating of 2 out of 10. We evaluated QNRX against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of QNRX have multiple concerns. QNRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

QNRX had negative earnings in the past year.
QNRX had a negative operating cash flow in the past year.
QNRX had negative earnings in each of the past 5 years.
In the past 5 years QNRX always reported negative operating cash flow.
QNRX Yearly Net Income VS EBIT VS OCF VS FCFQNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -58.92%, QNRX is in line with its industry, outperforming 41.92% of the companies in the same industry.
QNRX has a Return On Equity (-110.74%) which is in line with its industry peers.
Industry RankSector Rank
ROA -58.92%
ROE -110.74%
ROIC N/A
ROA(3y)-122%
ROA(5y)-105.72%
ROE(3y)-1177.47%
ROE(5y)-750.96%
ROIC(3y)N/A
ROIC(5y)N/A
QNRX Yearly ROA, ROE, ROICQNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -1K -2K -3K

1.3 Margins

QNRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNRX Yearly Profit, Operating, Gross MarginsQNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

QNRX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for QNRX has been increased compared to 5 years ago.
Compared to 1 year ago, QNRX has a worse debt to assets ratio.
QNRX Yearly Shares OutstandingQNRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 1B 2B 3B
QNRX Yearly Total Debt VS Total AssetsQNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 5M 10M

2.2 Solvency

Based on the Altman-Z score of -6.09, we must say that QNRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.09, QNRX is not doing good in the industry: 66.79% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.43 indicates that QNRX is not too dependend on debt financing.
QNRX's Debt to Equity ratio of 0.43 is on the low side compared to the rest of the industry. QNRX is outperformed by 73.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z -6.09
ROIC/WACCN/A
WACCN/A
QNRX Yearly LT Debt VS Equity VS FCFQNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 5M -5M

2.3 Liquidity

A Current Ratio of 3.35 indicates that QNRX has no problem at all paying its short term obligations.
The Current ratio of QNRX (3.35) is worse than 60.04% of its industry peers.
QNRX has a Quick Ratio of 3.35. This indicates that QNRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of QNRX (3.35) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.35
Quick Ratio 3.35
QNRX Yearly Current Assets VS Current LiabilitesQNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

QNRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.04%, which is quite impressive.
EPS 1Y (TTM)69.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 25.89% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.28%
EPS Next 2Y36.44%
EPS Next 3Y25.89%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNRX Yearly Revenue VS EstimatesQNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M
QNRX Yearly EPS VS EstimatesQNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1K -2K -3K -4K -5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QNRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QNRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNRX Price Earnings VS Forward Price EarningsQNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNRX Per share dataQNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as QNRX's earnings are expected to grow with 25.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.44%
EPS Next 3Y25.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QNRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (2/21/2025, 8:00:01 PM)

After market: 0.3213 +0 (+0.63%)

0.3193

-0.01 (-4.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-11 2025-03-11/amc
Inst Owners7.1%
Inst Owner Change852%
Ins Owners3.11%
Ins Owner Change98.69%
Market Cap2.61M
Analysts82.5
Price Target4.59 (1337.52%)
Short Float %0.77%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.93%
Min EPS beat(2)-43.19%
Max EPS beat(2)37.32%
EPS beat(4)3
Avg EPS beat(4)8.95%
Min EPS beat(4)-43.19%
Max EPS beat(4)37.32%
EPS beat(8)6
Avg EPS beat(8)13.8%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)7.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-4.05
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS0.91
TBVpS0.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.92%
ROE -110.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-122%
ROA(5y)-105.72%
ROE(3y)-1177.47%
ROE(5y)-750.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.35
Quick Ratio 3.35
Altman-Z -6.09
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.9%
EPS Next Y79.28%
EPS Next 2Y36.44%
EPS Next 3Y25.89%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.13%
OCF growth 3YN/A
OCF growth 5YN/A